ACOR - アコ―ダ・セラピュ―ティクス (Acorda Therapeutics Inc.) アコ―ダ・セラピュ―ティクス

 ACORのチャート


 ACORの企業情報

symbol ACOR
会社名 Acorda Therapeutics Inc (アコ―ダ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アコーダ・セラピューティクス(Acorda Therapeutics Inc.)はバイオ医薬品会社である。同社は神経障害患者を治療する療法の開発に従事する。同社は多発性硬化症(MS)患者の歩行を改善するための10ミリグラム(mg)のAmpyra(dalfampridine)延長放出錠剤を含む3件の米国食品医薬品局(FDA)承認治療薬を販売する。同社はまたZanaflexカプセルとタブレット、痙縮の管理のための短時間作用型の薬であるアメリカ食品医薬品局(FDA)認可薬及び帯状疱疹後神経痛関連の神経障害性疼痛の管理向けのFDA認可皮膚パッチであるQutenzaを販売する。同社はパーキンソン病、偏頭痛、多発性硬化症(MS)等の各種疾患を治療する神経療法のパイプラインを有する。同社の製品候補はレボドパの自己投与吸入用治療製剤であるCVT-301である。   アコ―ダ・セラピュ―ティクスは、米国のバイオ医薬品販売会社。多発性硬化症や脊髄損傷、および神経系の他の疾患の神経機能を改善する新しい治療法の開発および商業化を行う。また、チザニジン塩酸塩を含む「ザナフレックス」錠を販売する。本社は、ニューヨーク州ア―ズリ―。   Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
本社所在地 420 Saw Mill River Road Ardsley NY 10502 USA
代表者氏名 Ron Cohen ロン・コーエン
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 914-347-4300
設立年月日 34759
市場名 NASDAQ National Market System
ipoyear 2006年
従業員数 484人
url www.acorda.com
nasdaq_url https://www.nasdaq.com/symbol/acor
adr_tso
EBITDA EBITDA(百万ドル) 167.04000
終値(lastsale) 17.65
時価総額(marketcap) 838089299.45
時価総額 時価総額(百万ドル) 776.83520
売上高 売上高(百万ドル) 588.93000
企業価値(EV) 企業価値(EV)(百万ドル) 724.12520
当期純利益 当期純利益(百万ドル) -145.06100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Acorda Therapeutics Inc revenues increased less than 1% to $259.5M. Net income totaled $38M vs. loss of $27.1M. Revenues reflect Net product revenues increase of 3% to $253.4M also reflect License revenue decrease from $6.7M to $0K Royalty revenues decrease of 11% to $6.1M. Net income reflects Research and development - decrease of 40% to $54.8M (expense).

 ACORのテクニカル分析


 ACORのニュース

   The Battle of Fundamentals and Techniques: Acorda Therapeutics Inc. (ACOR)  2022/06/08 18:00:00 US Post News
Currently, Acorda Therapeutics Inc.’s (ACOR) stock is trading at $0.37, marking a gain of 2.34% from last night’s close. At this price, the stock is -94.16% below its 52-week high of $6.36 and 34.48% above its 52-week low of $0.28. Based on the past 30-day period, the stock price is -59.71% below the high and … The Battle of Fundamentals and Techniques: Acorda Therapeutics Inc. (ACOR) Read More »
   77 Biggest Movers From Yesterday  2022/06/01 09:02:22 Benzinga
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD ) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners. JanOne Inc. (NASDAQ: JAN ) gained 66.5% to close at $3.73 after the company announced it sold GeoTraq to SPYR Technologies in a $13.5 million transaction. Mullen Automotive, Inc. (NASDAQ: MULN ) jumped 44.9% to settle at $1.40 after the company announced results of its solid-state polymer battery testing with the Battery Innovation Center in Indiana. Studio City International Holdings Limited (NASDAQ: MSC ) gained 43.3% to close at $3.21. CatchMark Timber Trust, Inc. (NYSE: CTT ) shares climbed 42.1% to close at $11.79 after the company and PotlatchDeltic announced they have entered into a definitive agreement to combine in an all-stock transaction. Xcel Brands, Inc. (NASDAQ: XELB ) gained 36.7% to settle at $1.49 after the company announced WHP will purchase a controlling 70% interest in fashion brand Isaac Mizrahi.
   Acorda Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:ACOR)  2022/05/12 17:20:15 Seeking Alpha
The following slide deck was published by Acorda Therapeutics, Inc.
   The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More  2022/05/12 12:42:54 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology BridgeBio Pharma Inc (NASDAQ: BBIO ) has announced an exclusive license with Bristol Myers Squibb Co (NYSE: BMY ) to develop and commercialize BBP-398 in oncology. BridgeBio will receive an upfront payment of $90 million, up to $815 million in milestone payments and tiered royalties in the low- to mid-teens. BridgeBio will retain the option to acquire higher royalties in the U.S. in connection with funding a portion of development costs upon the initiation of registrational studies. BBIO shares are up 6.53% at $5.55 during the premarket session on the last check Thursday. FDA Green Lights Lava Therapeutics'' Blood Cancer Trial The FDA has signed off LAVA Therapeutics N.V''s (NASDAQ: LVTX ) investigational new drug (IND) application for LAVA-051, its lead product candidate for relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML).
   Acorda partners with Biopas to sell Parkinson''s disease therapy in Latin America  2022/05/11 20:16:09 Seeking Alpha
The commercial-stage biotech, Acorda Therapeutics (ACOR), and South American pharma company, Biopas Laboratories announced an agreement on Wednesday to commercialize Acorda’s…
   Orphan Drugs Market Huge Growth in Future Scope 2022-2028 | Acorda Therapeutics, Actelion Pharmaceuticals Ltd.  2022/04/05 09:34:01 OpenPR
The Orphan Drugs Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and secondary research strategies. the main purpose of this Orphan Drugs Market report is to supply an in-depth view
   Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2021 Results - Earnings Call Transcript  2022/03/10 02:21:04 Seeking Alpha
   Acorda Therapeutics rises postmarket after quarterly loss narrows 75%  2022/03/09 22:16:32 Seeking Alpha
Acorda Therapeutics (ACOR) is up 2% in after-hours trading following the biotech Q4 2021 and full-year earnings.
   Acorda Therapeutics Non-GAAP EPS of -$0.67, revenue of $36.07M beats by $5.06M  2022/03/09 21:03:02 Seeking Alpha
Acorda Therapeutics press release (NASDAQ:ACOR): Q4 Non-GAAP EPS of -$0.67.Revenue of $36.07M (-5.5% Y/Y) beats by $5.06M.
   Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results  2022/03/09 21:01:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
   Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022  2022/02/24 22:00:00 Business Wire
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
   Acorda Therapeutics Inc Shares Close in on 52-Week Low - Market Mover  2022/01/16 02:44:14 Kwhen Finance
Acorda Therapeutics Inc (ACOR) shares closed today at 1.4% above its 52 week low of $2.13, giving the company a market cap of $20M. The stock is currently down 9.6% year-to-date, down 66.1% over the past 12 months, and down 98.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 52.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -41.2% The company's stock price performance over the past 12 months lags the peer average by 373.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Acorda Therapeutics Inc Shares Close in on 52-Week Low - Market Mover  2022/01/10 01:08:12 Kwhen Finance
Acorda Therapeutics Inc (ACOR) shares closed today at 1.8% above its 52 week low of $2.25, giving the company a market cap of $21M. The stock is currently down 4.2% year-to-date, down 44.3% over the past 12 months, and down 98.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 41.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -62.2% The company's stock price performance over the past 12 months lags the peer average by 605.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Acorda Therapeutics Inc Shares Close in on 52-Week Low - Market Mover  2021/12/26 09:41:51 Kwhen Finance
Acorda Therapeutics Inc (ACOR) shares closed today at 1.7% above its 52 week low of $2.34, giving the company a market cap of $22M. The stock is currently down 42.5% year-to-date, down 45.2% over the past 12 months, and down 97.8% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 69.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 6228.0% The company's stock price performance over the past 12 months lags the peer average by 896.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Multiple Sclerosis Market to Witness Notable Growth by 2027 Covid-19 Analysis | Abbvie, Acorda Therapeutics  2021/12/15 10:19:30 OpenPR
This Multiple Sclerosis market report describes the factors that contribute to the sector''s development as well as market channels. When taken in order, this Multiple Sclerosis market report starts with an introduction to the commercial chain structure and then moves

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アコ―ダ・セラピュ―ティクス ACOR Acorda Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)